Proposed response parameters for 12 months drug trial in Juvenile Systemic Sclerosis. Results of the Hamburg International Consensus Meetings

By sjmartinez • June 19, 2023

Foeldvari I, Torok KS, Klotsche J, Anton J, Reis PC, Del Gado F, Denton C, Hinrichs B, Li SC, Pain C, Pilkington C, Cutolo M, Kasapcopur O, Khanna D, Ruperto N, Smith V, Furst DE. Proposed response parameters for 12 months drug trial in Juvenile Systemic Sclerosis. Results of the Hamburg International Consensus Meetings. Arthritis Care Res (Hoboken). 2023 Jun 18. doi: 10.1002/acr.25171. Epub ahead of print. PMID: 37332054.

Tags: Publications, Rheumatology

Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset

Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Frimodt-Møller[...]

Artificial Intelligence in Patch Testing: Comprehensive Review of Current Applications and Future Prospects in Dermatology

Tang HS, Ebriani J, Yan MJ, Wongvibulsin S, Farshchian M. Artificial Intelligence in Patch Testing: Comprehensive Review of Current Applications and Future Prospects in Dermatology.[...]

Author Correction: Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice

Özcan E, Yu KB, Dinh L, Lum GR, Lau K, Hsu J, Arino M, Paramo J, Lopez-Romero A, Hsiao EY. Author Correction: Dietary fiber content[...]